Abstract:Non-infectious uveitides (NIUs) encompass a varied group of inflammatory diseases affecting the uvea and adjacent tissues, with evidence suggesting an immune-mediated cause. A correct management of these conditions is essential to prevent substantial and sometimes permanent visual loss and the development of ocular complications. Although immunosuppressive drugs (ISDs) have shown effectiveness in achieving a sustained control of the inflammatory process, not all patients achieve a satisfactory response.To identify factors affecting the response rate to ISDs in subjects with NIUs.Longitudinal retrospective study, with patients collected from the Hospital Clinico San Carlos Uveitis Clinic, included from 1991 until December 2018, and followed-up until December 2019. Patients entered the study at ISD prescription and were followed-up until a) the achievement of a good therapeutic response (GTR), b) ISD treatment change (withdrawal of the prescribed ISD and/or addition of a new ISD), c) 12 months of follow-up, or d) loss of follow-up or end of the study (December 31th, 2019). GTR was defined as the complete resolution of the eye inflammatory manifestations and oral corticosteroid ≤10 mg of prednisone equivalent a day. Furthermore, this situation had to be maintained in at least two consecutive visits spanned at least 28 days. Kaplan-Meier (KM) curves were set to account for GTR. Associated demographic, clinical and treatment-related factors were analyzed using bivariate and multivariate Cox robust regression models. Different models were compared using the Akaike Information Criteria, to select the fittest model to the data. Proportional hazard assumption was tested using Schoenfeld residuals and the scaled Schoenfeld residuals. In case a variable or certain category of a categorical variable were non-proportional, they were included in the Cox models with a time-varying effect, in case the interaction with time was significant (p<0.05).73 patients (100 episodes of ISD prescription) were analyzed. In 44 episodes, a GTR was achieved (incidence rate 102.0 [95% Confidence Interval (CI): 75.9 to 137.1] per 100 patient-years). Figure 1 shows the KM curve for GTR. In the bivariate analysis, several variables showed a significant association with GTR, including gender, diagnosis of Behçet Disease, prescription of Cyclosporine A (CYA), number of previously prescribed ISDs, previous use of the same ISD, previous discontinuation of a ISD due to inefficacy, higher systemic corticosteroid use in the previous year before ISD prescription, presence of macular edema (ME), and longer intermediate and posterior activity before ISD prescription. Table 1 shows the results of the multivariate analysis. Prescription of CYA was associated with a higher hazard of GTR, compared with the use of other ISDs (methotrexate, azathioprine or biologic drugs). In addition, the higher dosage of oral corticosteroids used in the previous year before ISD prescription, the lower the hazard of achieving a GTR. Finally, presence of ME at prescription was associated with lower hazard of GTR, although this risk diminished with time.Table 1.Multivariate Cox robust regression to analyze variables independently associated with the achievement of good therapeutic response.VariableHR (95% CI)p valueSchoenfel test p valueCYA prescription2.04 (1.14-3.67)0.0170.56Number of previous ISDs0Reference--112.61 (2.07-76.73)5.9x10-30.001≥23.54 (1.55-8.05)2.6x10-30.561 previous ISD X Time0.01 (0.001-1.00)0.005Higher oral corticosteroids dosage (mg) in the previous year0.98 (0.97-0.99)0.0130.83Macular edema0.14 (0.04-0.45)9.3x10-30.001Macular edema X Time14.20 (1.55-103.10)0.019Figure 1.Kaplan-Meier failure curves representing good therapeutic response after immunosuppressive drug prescription for non-infectious uveitis.We have identified several variables associated with therapeutic response to ISDs in NIUs patients.None declared

Efficacy and safety of immunomodulatory drugs in patients with non-infectious intermediate and posterior uveitis, panuveitis and macular edema: A systematic literature review

Use of immunomodulators in non-infectious uveitis: lights and shadows

The efficacy of Golimumab against non-infectious uveitis: a PRISMA-compliant systematic review and meta-analysis

An Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis

Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-Infectious Uveitis Treatment: A Review

POS1354 ANALYSIS OF FACTORS ASSOCIATED WITH GOOD THERAPEUTIC RESPONSE TO IMMUNOSUPPRESSIVE DRUGS IN PATIENTS WITH NON-INFECTIOUS UVEITIS: A SURVIVAL ANALYSIS

Non-anti-TNF biologic modifier drugs in non-infectious refractory chronic uveitis: The current evidence from a systematic review

Nano-based Drug Delivery Systems for the Treatment of Non-Infectious Uveitis

Update on the systemic management of noninfectious uveitis in children and adolescents

Efficacy, safety and cost-effectiveness of methotrexate, adalimumab or their combination in non-infectious non-anterior uveitis: a protocol for a multicentre, randomised, parallel three arms, active-controlled, phase III open label with blinded outcome assessment study

Biological and Therapeutic Role of Interleukin-6 in Non-Infectious Uveitis: A Narrative Review

Review of the Effectiveness of Modern Treatment of Non-Infectious Uveitis

Efficacy and safety of iguratimod in the treatment of rheumatic and autoimmune diseases: a meta-analysis and systematic review of 84 randomized controlled trials

New therapies in development for the management of non‐infectious uveitis: A review

Immunomodulatory treatment vs. systemic steroids in inflammatory choroidal neovascularization secondary to idiopathic multifocal choroiditis

Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries

Intravitreal steroid implants in the management of noninfectious intermediate and posterior uveitis

Immunopharmacotherapy of non-infectious uveitis: where do we stand?

The Efficacy and Safety of Adalimumab in Treating Pediatric Noninfectious Chronic Anterior Uveitis With Peripheral Retinal Vascular Leakage: A Pilot Study

Ocular involvement in adult and paediatric patients with monogenic autoinflammatory diseases: a Spanish multicentre retrospective study